Prelude Therapeutics Incorporated announced a private placement with certain institutional accredited investors for issuance of 7,936,759 pre-funded warrants at a price of $3.1499 per warrant for gross proceeds of $24,999,997.1741 on December 11, 2023. The warrants have an exercise price of $0.0001 per share. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about December 13, 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.16 USD | +4.00% | +0.25% | -4.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.45% | 220M | |
+33.34% | 49.46B | |
+1.74% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.81% | 26.61B | |
-22.11% | 18.64B | |
+7.83% | 13.16B | |
+29.52% | 12.55B | |
+24.26% | 12.1B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding